Continue from research to sourcing
Compare CJC-1295 listings without losing the evidence context
The CJC-1295 name is used for materially different catalog products. A useful comparison must separate DAC and no-DAC listings before evaluating price or documentation.
Identity first
Determine whether the material includes the drug-affinity-complex modification or is a no-DAC modified GHRH product. Those records should not be merged.
Normalize price
Compare price per mg only within the same documented molecular form and vial size context.
Inspect evidence
Require the sequence, modification status, expected mass, lot and identity result to agree across the listing and report.
How CJC-1295 is used in research
CJC-1295 was developed to prolong exposure to a GHRH-like signal. Early human research measured growth hormone and insulin-like growth factor 1 responses after administration.
The name is used inconsistently in commercial catalogs. Materials described as CJC-1295 without DAC may refer to a shorter-acting modified GRF sequence rather than the drug-affinity-complex version studied in key publications.
Evidence map
Research stage matters. Findings from one model should not be silently promoted to another.
Laboratory
Receptor and stability work informed the analog’s design.
Animal
Preclinical endocrine studies preceded human development.
Human
Small early-phase studies measured endocrine biomarkers; there is no FDA-approved CJC-1295 drug.
What the evidence does not establish
Short biomarker studies do not establish long-term benefit or safety. Commercial naming ambiguity can make literature-to-product comparisons invalid.
Study findings also do not authenticate a supplier’s material. Biological plausibility, a familiar name, or a published paper cannot substitute for lot-specific identity and quality evidence.
Analytical and documentation checks
The test plan should match the exact molecule, modification, and research question.
- Determine whether the material includes the DAC modification.
- Confirm sequence, modification site, and expected mass.
- Reject documents that use CJC-1295 and modified GRF interchangeably without specification.
At minimum, connect the product name, sequence, sample identifier, lot, report, method, expected result, and observed result. Record untested attributes as “not reported,” not as assumed passes.
Build the documentation record
Regulatory status
CJC-1295 is not an FDA-approved drug. Early-phase human research does not authorize consumer marketing.
Regulatory status can change and attaches to specific products and jurisdictions. Verify current official records before publishing, procuring, or relying on a status claim.
Primary sources and official records
Use these records as starting points, then assess the exact model, test article, methods, and date:
Peptide Due Diligence Research Brief
Follow the evidence, not the headline.
Receive new evidence maps, documentation guides, and material corrections as the directory expands.
By subscribing, you agree to receive PDD research emails. Unsubscribe at any time.
Already subscribed? Get your free checklist.